Answers are grounded in this paper and cite their sources.
Randomized trial compares efficacy of cytisinicline and varenicline for smoking cessation, highlighting improved tolerance.
Rationale Pharmacologic options for supporting smoking cessation remain limited. Although varenicline is an effective treatment option, its use may be restricted by a high rate of discontinuation, due to side effects such as nausea. Cytisinicline is a plant-based alkaloid that selectively binds to α4β2 nicotinic acetylcholine receptors, reducing nicotine craving and withdrawal symptoms, thereby limiting nicotine’s reinforcing effects with minimal interaction with the serotonin receptors responsible for nausea. Cytisinicline has proven effective for smoking cessation in the Phase 3 ORCA-2 and ORCA-3 trials, with a favorable safety profile. In the absence of large head-to-head randomized controlled trials, this analysis compared the relative efficacy and safety of cytisinicline versus varenicline using an indirect treatment comparison. Methods A matching-adjusted indirect comparison was conducted to compare 12- and 24-week treatment outcomes with a novel 3 mg cytisinicline formulation dosed three times daily (ORCA-2 and ORCA-3) and varenicline 1 mg twice daily (Phase 3 EAGLES trial). Efficacy outcomes were biochemically confirmed continuous smoking abstinence rate from Weeks 9-12 and Weeks 9-24 reported as odds ratios (ORs). Safety outcomes included treatment discontinuation due to treatment-emergent adverse events (TEAEs), and the most commonly reported AEs for both agents (nausea, insomnia, abnormal dreams). De-identified individual patient data from ORCA-2 and ORCA-3 were weighted to match key baseline characteristics of the EAGLES trial non-psychiatric cohort using propensity score weighting. Efficacy (continuous abstinence rate at Weeks 9-12 and 9-24) and safety were evaluated in both adjusted and unadjusted analyses to assess the impact of weighting on relative effect estimates and uncertainty. Results The continuous abstinence rate was comparable for cytisinicline and varenicline cohorts at the 9-12-week assessment (Table; adjusted ORs 1.32-1.33). Abstinence rates were higher for cytisinicline versus varenicline at the 9-24-week assessment (Table; adjusted ORs 1.90-2.13). Cytisinicline was associated with a markedly lower rate of nausea versus varenicline (adjusted ORs: Set 1, 0.18 [95% confidence interval 0.10-0.31]; Set 2, 0.16 [0.09-0.29]; Set 3, 0.13 [0.07-0.26]). ORs for all-cause discontinuations (adjusted ORs 0.78-0.89), insomnia and abnormal dreams (adjusted ORs 0.84-1.43) were comparable between the two treatments. Conclusions Cytisinicline demonstrated comparable end-of-treatment efficacy and superior longer-term efficacy versus varenicline for smoking cessation, with a significantly lower frequency of nausea. These findings suggest that cytisinicline may be a more tolerable and effective alternative, especially for patients at risk of relapse or unable to tolerate varenicline.
No takes yet. Share an insight, caveat, or question.
Rubinstein et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: